Antoni Ribas, MD, PhDProfessor of Medicine, Surgery, and Molecular and Medical Pharmacology, University of California Los Angeles

Antoni Ribas is professor of medicine, surgery, and molecular and medical pharmacology at the University of California Los Angeles (UCLA) and director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC). Ribas is a physician-scientist conducting laboratory and clinical translational research in how melanoma responds or resists to cancer immunotherapies, and developing gene engineered adoptive cell transfer therapies. He has been instrumental in the clinical development of several agents approved by the FDA, including the first anti-PD-1 pembrolizumab (Keytruda), the anti-CTLA-4 tremelimumab (Imjudo), as well as two combinations of BRAF and MEK inhibitors, vemurafenib (Zelboraf) and cobimetinib (Cotellic), and dabrafenib (Tafinlar) and trametinib (Mekinist). He is a past president of the American Association for Cancer Research (AACR), an elected Fellow of the AACR Academy, the American Society for Clinical Investigation, the Association of American Physicians and the US National Academy of Medicine.